Correlation Between Supreme Cannabis and Takeda Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Supreme Cannabis and Takeda Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Supreme Cannabis and Takeda Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between The Supreme Cannabis and Takeda Pharmaceutical Co, you can compare the effects of market volatilities on Supreme Cannabis and Takeda Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Supreme Cannabis with a short position of Takeda Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Supreme Cannabis and Takeda Pharmaceutical.

Diversification Opportunities for Supreme Cannabis and Takeda Pharmaceutical

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Supreme and Takeda is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding The Supreme Cannabis and Takeda Pharmaceutical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Takeda Pharmaceutical and Supreme Cannabis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on The Supreme Cannabis are associated (or correlated) with Takeda Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Takeda Pharmaceutical has no effect on the direction of Supreme Cannabis i.e., Supreme Cannabis and Takeda Pharmaceutical go up and down completely randomly.

Pair Corralation between Supreme Cannabis and Takeda Pharmaceutical

If you would invest (100.00) in The Supreme Cannabis on December 29, 2023 and sell it today you would earn a total of  100.00  from holding The Supreme Cannabis or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

The Supreme Cannabis  vs.  Takeda Pharmaceutical Co

 Performance 
       Timeline  
Supreme Cannabis 

Risk-Adjusted Performance

0 of 100

 
Low
 
High
Very Weak
Over the last 90 days The Supreme Cannabis has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Supreme Cannabis is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders.
Takeda Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Low
 
High
Very Weak
Over the last 90 days Takeda Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Takeda Pharmaceutical is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.

Supreme Cannabis and Takeda Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Supreme Cannabis and Takeda Pharmaceutical

The main advantage of trading using opposite Supreme Cannabis and Takeda Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Supreme Cannabis position performs unexpectedly, Takeda Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will offset losses from the drop in Takeda Pharmaceutical's long position.
The idea behind The Supreme Cannabis and Takeda Pharmaceutical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
FinTech Suite
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories